Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo goals were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, w